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Abstract
Background: Breast cancers that overexpress the human epidermal growth factor receptor 2
(HER2) are eligible for effective biologically targeted therapies, such as trastuzumab. However,
accurately determining HER2 overexpression, especially in immunohistochemically equivocal cases,
remains a challenge. Manual analysis of HER2 expression is dependent on the assessment of
membrane staining as well as comparisons with positive controls. In spite of the strides that have
been made to standardize the assessment process, intra- and inter-observer discrepancies in
scoring is not uncommon. In this manuscript we describe a pathologist assisted, computer-based
continuous scoring approach for increasing the precision and reproducibility of assessing imaged
breast tissue specimens.
Methods:  Computer-assisted analysis on HER2 IHC is compared with manual scoring and
fluorescence in situ hybridization results on a test set of 99 digitally imaged breast cancer cases
enriched with equivocally scored (2+) cases. Image features are generated based on the staining
profile of the positive control tissue and pixels delineated by a newly developed Membrane
Isolation Algorithm. Evaluation of results was performed using Receiver Operator Characteristic
(ROC) analysis.
Results: A computer-aided diagnostic approach has been developed using a membrane isolation
algorithm and quantitative use of positive immunostaining controls. By incorporating internal
positive controls into feature analysis a greater Area Under the Curve (AUC) in ROC analysis was
achieved than feature analysis without positive controls. Evaluation of HER2 immunostaining that
utilized membrane pixels, controls, and percent area stained showed significantly greater AUC than
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manual scoring, and significantly less false positive rate when used to evaluate
immunohistochemically equivocal cases.
Conclusion: It has been shown that by incorporating both a membrane isolation algorithm and
analysis of known positive controls a computer-assisted diagnostic algorithm was developed that
can reproducibly score HER2 status in IHC stained clinical breast cancer specimens. For equivocal
scoring cases, this approach performed better than standard manual evaluation as assessed by ROC
analysis in our test samples. Finally, there exists potential for utilizing image-analysis techniques for
improving HER2 scoring at the immunohistochemically equivocal range.
Background
Clinical Introduction
The human epidermal growth factor receptor 2 (HER2)
gene on chromosome 17 is amplified in 20% to 30% of
breast cancer patients [1]. The protein product is a trans-
membrane receptor tyrosine kinase whose overexpression
in breast cancers is predominantly due to HER2 gene
amplification [2]. The proper evaluation of HER2 status is
crucial to patient care as its overexpression and/or ampli-
fication is associated with less favorable clinical outcomes
and relatively poor response to certain treatments [3,4].
Moreover, with the development of effective targeted ther-
apies such as Trastuzumab (Herceptin), a monoclonal
antibody to HER2, which are effective only in tumors with
HER2 overexpression, the clinical ramifications of accu-
rately assessing HER2 status is further underscored. Thus,
accurate HER2 assessment is vital to the identification of
breast cancer patients who would benefit from anti-HER2
therapy.
Given the clinical impact of HER2 overexpression, there
has recently been a heightened emphasis on reliably
assessing HER2 status in breast cancers [5-9]. Guidelines
have been issued jointly by the American Society of Clin-
ical Oncology (ASCO) and the College of American
Pathologists (CAP) in order to establish protocols for
evaluating HER2 status that involve both immunohisto-
chemistry (IHC) and fluorescence in situ hybridization
(FISH) [6,10]. Recently a new standard for assessing HER2
expression was instituted that requires that both IHC and
FISH be conducted when scores from either fall into the
newly established equivocal ranges. ASCO/CAP recom-
mended that an IHC score of 2+ or a FISH score (ratio of
HER2/CEP17 genes) of 1.8–2.2 be considered equivocal
and that the specimen be graded with the complementary
modality, or repeated in the case of FISH. (An alternate
option is to reassess the immunohistochemistry at a refer-
ence laboratory.)
In light of the pressing need for accurate determination of
HER2 overexpression, the authors of the above ASCO/
CAP study have acknowledged the use of image analysis as
a viable approach for assessment. Previous work with
image analysis systems have focused on the validation of
commercially available technology in the clinic by dem-
onstrating greater accuracy in quantification of HER2
immunohistochemistry when compared to manual inter-
pretation [4,11-13], and reduction in inter-observer varia-
bility with systems such as ACIS (automated cellular
imaging system) [13]. However, due to the proprietary
nature of such systems, the technical processes that lead
up to a HER2 score are often not transparent to the pathol-
ogist. This may lead to interpretation difficulties as the
exact tissue features being quantified and the methods
used to perform the HER2 assessment have not been
made available for peer review. For instance, the patholo-
gist has little information regarding how well and to what
extent the image analysis software is able to quantify
membrane staining. Furthermore, the pathologist does
not have access to the manufacturer's criteria or data that
established the universal "cutoff score" for HER2 positiv-
ity [11]. This can be problematic as cutoff values are not
necessarily applicable across laboratories due to varia-
tions in staining characteristics which can arise as a result
of different choices in antibodies, laboratory equipment,
and fixation procedures [14]. Veiling the relevant techni-
cal information that is used to render clinical decisions is
somewhat inconsistent with the current environment of
evidence-based medicine. In the face of these pressing
concerns, to our knowledge, only one commercial system
has revealed some basic outlines of the image processing
methods behind their commercially based system [15].
Furthermore, the cost of performing the analysis may
actually serve as a barrier to mainstream adoption of this
technology in practice. Skaland et. al. has contributed val-
iantly in this realm by using readily available (and free)
NIH image processing software to analyze images of
HER2 stained breast cancer specimens [16]. However,
these algorithms use generic image processing methods
not designed specifically for these images. For instance, no
morphologically based operators are used to detect
stained membrane pixels, but rather a simple intensity
threshold is used. Therefore, only darkly stained images
could be analyzed in their experiments. As a result, we
have tried to introduce algorithms specifically tailored to
this application.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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In this manuscript, we describe the design, development
and evaluation of a new suite of algorithms to assist in
increasing the precision (i.e. number of scoring levels) at
which HER2 immunostains are quantified. We provide a
detailed description of the workflow and associated proc-
esses that are used to evaluate HER2 stained breast slides
and compute the HER2 expression score. We describe
three clinically based image features used in our system
and compare their performance with manual scoring tech-
niques in assessing specimens. The performance results of
the computer-assisted quantification algorithms based on
the newly developed image features are then compared
with manual scoring using Receiver Operator Characteris-
tic (ROC) analysis. In addition, the adequacy of the quan-
tification algorithm is crucially examined in the equivocal
scoring ranges in order to demonstrate its applicability in
the laboratory. Finally, we discuss the capacity of the sys-
tem to be optimally calibrated for the specific conditions
of the given laboratory. By increasing the precision with
which HER2 immunohistochemistry is quantified, we
anticipate that breast cancer patients who might benefit
from anti-HER2 therapy will be accurately identified,
while the remaining subpopulation of patients will be
spared a costly and potentially harmful treatment.
Designing the Computer-Assisted Quantification Scheme
In order to design a clinically relevant computer-based
quantification scheme, we first begin by examining the
current methods that are used routinely in the laboratory.
Briefly, the pathologist focuses on two primary features to
arrive at a HER2 score: the quality of membrane staining
(since HER2 is a receptor functioning at the cytoplasmic
membrane) and the percent of invasive tumour cells
stained (Table 1). In this first attempt at developing a new
approach for conducting computer-assisted quantifica-
tion of specimens, we will address and evaluate the per-
formance of this system based on steps A, B, C, E, and F as
shown in Table 1. In this computer-assisted framework,
the pathologist will perform Steps A and B. A membrane
isolation algorithm will be introduced to account for Step
C, and an approximation method will be used to account
for Step E. In addition, guided by the fact that the staining
characteristics of the control are taken into account during
the manual assessment of immunostains (Step F) [17], we
introduce computer-assisted analysis of a known positive
control (V) into our computations. This is a feature that is
not utilized in most commercial systems. Step D is an area
left for future investigation.
Methods
Overview of Computer-Assisted Quantification Scheme
The workflow of the quantification scheme is outlined in
Figure 1. Standard formalin-fixed, paraffin-embedded
HER2 IHC stained diagnostic sections of breast tissue are
visualized using diaminobenzidine (DAB) and counter-
stained with hematoxylin. A relevant microscopic field of
the tissue is digitally imaged by a certified pathologist. All
pixels which are stained with DAB, indicating areas of
HER2 protein, are isolated by utilizing a color decompo-
sition algorithm that was previously described [18]. Sub-
sequently, image-based quantification of HER2 staining
proceeds through identifying stained membrane regions
using a filter-based algorithm (II) and comparison with
positive controls (V). Lastly, we provide a gross estimate
of the percentage of positive tumor cells (IV) by factoring
the percentage of stained area (expressed in pixels) into
the feature analysis.
Case selection, processing, and manual grading
The specimens used in these studies consisted of 99 breast
cancer cases that had been diagnosed between January
2005 and March 2007 and stored in archives at the
Department of Pathology and Laboratory Medicine at
Robert Wood Johnson University Hospital, New Bruns-
wick, and N.J. During this period of time it was standard
procedure for both assays to be performed. Cases which
had received an IHC score of 0 or 1+ were limited in order
to enrich the amount of 2+ cases (considered equivocal)
to approximately 25% of the data. The purpose of this
experimental design was that since 2+ cases are considered
equivocal, they represent the patient population that
would tend to benefit most from the use of computer
aided quantification. Specimens with significant mechan-
ical crushing and sectioning artifacts were omitted from
the study to arrive at the final 99 cases. Both invasive duc-
tal and lobular carcinomas were included in the experi-
ments.
Table 1: Translating Manual HER2 Assessment into Computer-Related Tasks
Pathologist Computer
A. Visually examines tissue I. Captures digital image of relevant area of tissue
B. Locates invasive carcinoma
C. Examines intensity of stain at cytoplasmic membrane II. Identifies stained membrane areas (pixels) and quantifies intensity on 0–255 scale
D. Examines completeness of membrane staining III. Quantifies percentage of membrane staining per cell
E. Examines percent positive cells IV. Counts positive cancer cells and divides by total number of cancer cells
F. Compares with positive tissue controls V: Takes digital image of control, quantifies control, and uses it to normalize patient 
HER2 score.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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Immunohistochemical staining was performed at the
Department of Pathology and Laboratory Medicine at
Robert Wood Johnson University Hospital utilizing an
automated immunostainer, Ventana BenchMark IHC/ISH
system (Ventana Medical Systems, Inc. Tucson, AZ). Ven-
tana PATHWAY HER-2 (clone CB-11) was used for the
primary detection of c-erbB-2 antigen in sections of for-
malin fixed, paraffin embedded tissue. A known 3+, FISH
positive control was fixed on each slide along with the
patient sample in order to analyze both under identical
staining conditions.
Manual immunohistochemical grading was performed by
a board certified surgical pathologist (P.J.) at Robert
Wood Johnson University Hospital according tithe Scor-
ing Guide for the Interpretation of Ventana Pathway
HER2 Staining of Breast Carcinomas [19]. Briefly, if no
membrane staining was observed the specimen was
scored as 0. Faint, partial staining of the membrane was
scored as 1+. Weak complete staining of the membrane,
>10% of cancer cells was scored as 2+. Intense complete
staining of the membrane, >10% of cancer cells, was
scored as 3+. A score of 2+ or greater is considered positive
according to the manufacturer's instructions.
Specimens were sent to Genzyme Genetics (Westborough,
MA) for FISH analysis and the ratio of discrete signals for
the HER2 gene and centromere probe for chromosome 17
(CEP17) was reported. A ratio of HER2 gene/CEP17 ≥ 2.3
was considered positive for HER2 overexpression.
Image Selection and Capturing
A board certified pathologist (P.J.) delineated the region
of invasive carcinoma, and then a resident pathologist
(M.I.) used a robotic microscope to digitally acquire
images at 20× magnification within the specified bound-
Overview of computer-assisted image analysis scheme Figure 1
Overview of computer-assisted image analysis scheme. The process of transforming a slide into a score begins with the 
pathologist capturing a digital image. A color decomposition algorithm is performed in order to isolate the DAB stain (brown 
areas) from the hematoxylin stain (blue areas). Next, a membrane isolation algorithm, utilizing a set of bar filters, isolates the 
relevant stained membrane pixels. Finally, based on these pixels, a HER2 score can be computed. The process is repeated in 
order to take into account the positive control.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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aries. The control from each slide was also digitized at 20×
magnification. All images are taken with an Olympus
AX70 microscope (Olympus America Inc., Melville, NY)
equipped with a Prior six-way robotic stage and motor-
ized turret (Prior Scientific, Inc., Rockland, MA) and
Olympus DC330 720-line 3-Chip video camera at 1360 ×
1024 pixel resolution and a fixed exposure time of 1/600
s. This allows the digital images to be captured through
red, green, and blue channels, and thus, span the entire
visible range.
Color Decomposition
The DAB (HER2) stained regions were isolated from the
hematoxylin counterstain in the digital image of the
patient sample and control images through the use of
color decomposition (Fig. 2) [18]. Based on a polar trans-
formation in a color space where the hematoxylin and
DAB colors are laid out on a super-plane, color decompo-
sition enables the digital image to be separated into the
hematoxylin stained image and the DAB stained image of
the tissue. In a sense, this algorithm attempts to describe
light absorbance from certain color ranges (DAB and
Hematoxlyin) without the use of expensive spectral imag-
ing equipments.
Membrane Isolation Algorithm (MIA)
In order to isolate the membrane stained regions, Otsu's
method [20] was used to preprocess the DAB image by
automatically removing background noise. Subsequently,
a rotationally invariant bar filter was used to detect mem-
branes throughout the DAB stained image. The rotation-
ally invariant filter was created using a set of eight
Gaussian based bar filters rotated 2π/8 degrees apart
(details in Fig. 3). Similar to [21], rotational invariance is
achieved by keeping only the maximum response from
the convolution of these 8 filters with the DAB image. Var-
Color Decomposition Figure 2
Color Decomposition. This is an example image of a breast cancer specimen stained for HER2 using DAB as the chromagen 
and counterstained with hematoxylin. Color Decomposition [18] is applied to the original image and as a result, a gray scale 
DAB stained image plane and a hematoxylin stained image plane is produced.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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ious thresholds were then applied to the maximum
response from convolution with the bar filters. The
thresholds (k = [1,5,7,9,12,15,20]) used to isolate mem-
brane pixels were evaluated based on their ROC perform-
ance. In the results below, only k = 15 data is shown. ROC
data were calculated for all thresholds k (see Additional
file 1). Membrane isolation results on lighter stained spec-
imens are upon inspection visually more satisfying (see
Additional File 2). However experiments conducted using
lower thresholds for lighter stained images and higher
thresholds for darker images, provided no added benefit
in terms of increasing AUC (see Additional file 3).
Image Features and HER2 Score
In these experiments, three scoring features based on
mean intensity were reported. The first image feature used
to calculate a score is Mp  the mean intensity of the
patient's stained membrane regions,
where I is the set of intensities derived from the pixels
retained from performing the MIA on p the patient tissue;
the bar denotes the mean function.
2. The second image feature is Mn which is Mpnormalized
by the positive control
Mc is defined similarly to Mp except that the calculation is
based on c the control tissue  .
3. The third feature Ma adds a coefficient d/N, to Mn
where N is the total amount of pixels in the image, d is the
number of DAB stained pixels after pre-processing. The
coefficient d/N is used as an approximation for the per-
centage of stained cells. Results were also gathered for
median-based features; however, results were similar, and
therefore not included in this manuscript.
Hardware and Implementation
An Intel Core 2 Duo T7400 (2.16 GHz) computer with 1.0
GB memory was used for processing each image. The
color decomposition algorithm was implemented in Java.
All other processing was implemented utilizing Matlab
(The MathWorks, Inc. Natwick, MA) code. The color
decomposition and membrane isolation together took
approximately 10–20 seconds per image to complete.
Statistical Analysis
Receiver Operator Characteristic curve analysis was used
to compare the accuracy of the manual and automated
computerized methods for grading IHC. FISH assays were
used as an independent means for assessing IHC scores.
The area -under- the -curve (AUC) was calculated for each
ROC curve utilizing the trapezoidal rule [22] in order to
compare the accuracy of each method as a test for FISH
positivity. Since the data are derived from the same
patient cases, p-values are calculated using a nonparamet-
ric method based on the Mann-Whitney-U Statistic [22].
The McNemar Test for correlated proportions [23,24]was
used to calculate the p-values for differences between sen-
sitivity or specificity.
Institutional Review Board Approval
Institutional Review Board approval was obtained for this
retrospective study through protocol (IRB #5381).
Results
Case Selection
Table 2 summarizes the HER2 expression as determined
by FISH and manual grading for these 99 cases. Similar to
[25], our data included cases in which the gene was found
to be amplified, but protein levels determined by IHC
were not overexpressed (IHC < 2+), and cases where IHC
= 3+, in which there was no gene amplification.
MI pp = (1) (1)
M
Mp
Mc
n = . (2) (2)
MI cc =
M d
N M an = (3) (3)
Rotationally invariant bar filter Figure 3
Rotationally invariant bar filter. Eight bar filters, each 
successively rotated 2π/8 degrees, are used to detect the 
cytoplasmic membrane through a convolution with the DAB 
stained image. The Gaussian-based bar filter is centered on a 
25 × 25 pixel base, with (σx, σy) = (5,1), thus creating an 
elongated bar. The filters as a set are rotationally invariant as 
only the maximum response from the convolution is chosen. 
A view of these filters as an image where higher values are 
depicted brighter is shown.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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Analysis of Specimens using Stained Membrane Regions 
with and without controls
Two examples of HER2 stained images (Fig. 4) are shown.
The pixels chosen after applying the membrane isolation
algorithm are visualized by red areas overlaying the origi-
nal image. It is important to note that biologically irrele-
vant cytoplasmic pixels were not selected since the HER2
receptor is a transmembrane protein functioning at the
cytoplasmic membrane.
Figure 5 shows the variations in staining intensities of the
membrane regions of known HER2 positive controls
(taken from breast specimens that are FISH positive and
previously manually scored as 3+) used in this study.
Though most control specimens stain dark, there is
indeed variation in intensity which should be taken into
account when computing a HER2 score. Hence, we have
chosen to derive the Mn feature which specifically takes
into account the intensity of the positive control.
Figure 6 displays the results of three scoring methods:
user-guided image analysis based on Mn, FISH, and stand-
ard manual scoring. It is shown that the image-based sys-
tem is capable of delineating two groups of patients: those
with high Mn scores and gene amplification, and those
with low Mn scores and no amplification. The classifica-
tion of several cases has improved with computer-assisted
image analysis (arrows). When image analysis was per-
formed, four IHC 3+ cases (but FISH-) are clustered with
the non-amplified group, while a 2+ case with genetic
amplification is grouped with other FISH positive cases.
Also, it is important to note that, the Mn score for some
cases was computed to be beyond a ratio of one, indicat-
ing that these patient tissues stained darker than the con-
trol tissue, which possibly suggests a greater concentration
of HER2 protein than the control tissue.
In order to quantitatively compare these scoring systems,
a ROC curve was generated comparing the diagnostic reli-
ability of the Mn and Mp features with that of manual scor-
ing (Fig. 7). The optimal ROC curve is one that
approaches the upper left-hand corner, with an AUC of 1.
Our results show that the area under the Mn curve (0.87)
is significantly greater than the Mp curve (one tailed, p <
.05), indicating that quantitatively utilizing the control
provides a better diagnostic test than analyzing only
patient tissue. When the AUC of the Mn curve was com-
pared to that of manual assessment, no significant differ-
ence was found (two tailed, p > .14).
Analysis of Specimens using Stained Membrane Regions 
incorporating Both Controls and Percent Stained Area
The results from Figure 7 indicated that the performance
of the system based on Mn score was similar to that of
manual scoring. Consequently, the percent stained area
was incorporated into the Ma feature through an addition
of the d/N coefficient. The Ma ROC curve (red line) is com-
pared to the ROC curve generated from manual scoring
(black line, Fig. 7). As evident in this plot, the AUC from
the Ma feature is significantly greater than that derived
from manual scoring (p < .05). More importantly, the dif-
ference between the two scoring systems is most pro-
nounced at the clinically crucial point: the equivalent
score of 2+. The arrow (Fig. 7) denotes an example Ma cut-
off point that has a statistically lower false positive rate
than that derived by using the 2+ cutoff score.
Quantification of Equivocal Cases
Lastly, these computer-assisted scoring methods can be
engineered to perform optimally on equivocal cases. Fig.
8 reports the ROC curve for the scores generated by Ma
and Mn based solely on the 22 manually scored 2+ cases.
A specific true positive or false positive rate based on clin-
ical needs can be selected by plotting this ROC curve. For
100% detection of FISH amplified cases (sensitivity of 1),
Results of the membrane isolation algorithm Figure 4
Results of the membrane isolation algorithm. Two 
examples of HER2 images (left column) taken from a manu-
ally graded 3+ case (top row) and 2+ case (bottom row) with 
their isolated membrane regions (right column). Images are 
captured at 20× magnification and stained with DAB and 
hematoxylin.
Table 2: Summary of HER2 manual grading and FISH scores
FISH Score IHC = 0 IHC = 1 IHC = 2 IHC = 3 Total
≤ 1 . 7 2 52 21 5 6 6 8
1.8 – 2.2 1 1 2 0 4
≥ 2.3 2 3 5 17 27
T o t a l 2 82 62 22 3 9 9BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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note how the computer-assisted scoring system can signif-
icantly reduce false positive rates (arrows) for IHC = 2+
cases (p < .05), as Ventana scoring guidelines considers all
2+ cases weakly positive.
To estimate a robust classification performance of the sys-
tem on only these 2+ cases, an iterative leave-one-out clas-
sification experiment was performed. The cutoff point to
determine FISH positivity was based on twenty-one train-
ing samples. This cutoff point was chosen as the maxi-
mum cutoff point yielding 100% sensitivity (i.e. fix
sensitivity at 100% while maximizing specificity). Then
the novel case not used in training was scored based on
the cut-off score. Correct was defined as either above the
cut-off and FISH ≥2.3 (a true positive decision), or below
the cut-off score and FISH <2.3 (a true negative). Repeat-
ing the experiment 1000× with a randomly chosen test
case, we arrived at an estimate of the system's classifica-
tion performance on 2+ cases. From this experiment, the
2+ test case was correctly classified 64%  of the time,
whereas manual scoring was only able to correctly classify
23% of the cases (5/22: 5 of the 22 2+ cases, which are
considered positive, were also FISH positive). There was a
reduction false positive rate (percentage of FISH negative
cases considered FISH positive) from 100% to 31%, as
100% of manually scored 2+ cases are considered by Ven-
tana scoring guidelines to be positive. Lastly, the false neg-
ative rate was only 4%.
Discussion
In this retrospective study of 99 cases of breast carcinoma,
we have demonstrated the processes and methods behind
the design, development, and evaluation of an image-
based, computer-assisted HER2 immunohistochemistry
quantification scheme. The result was an introduction of
a membrane isolation algorithm and the quantitative use
of positive staining controls. The membrane isolation
algorithm in combination with the quantitative use of
controls (Mn feature) was shown to be superior to analyz-
ing the patient tissue alone (Mp feature). This improve-
ment is hypothesized to stem from the unique staining
conditions of each slide that is reflected in both the
patient and control sample. Furthermore, this clinically
based combination (Mn) demonstrated an ability to corre-
Variations on the Membrane Staining Intensities of Positive Control Specimens Figure 5
Variations on the Membrane Staining Intensities of Positive Control Specimens. This is a histogram showing the 
amount of specimens in each range of intensities. Each bar contains cases that lie within a 20 unit range of intensities. Though 
most positive controls stain darkly (215–235), there is a significant number of cases in which staining intensity deviates mark-
edly from the mode. Consequently, features that take into account the intensity of the positive control are used in this study.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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late with gene amplification results that was similar to
that of manual assessment.
With the establishment of new guidelines defining the
equivocal IHC scoring range of 2+, it was hypothesized
that computer-assisted image analysis may be useful in
assisting in the manual interpretation of these cases. As a
result, we explored the addition of an area coefficient to
the Mn feature to form the Ma feature. Using this feature,
significant reduction in false positive rate was evidenced
especially in the 2+ intensity region (Fig. 7), along with an
overall greater AUC than manual grading. A greater AUC
is interpreted as a greater probability that a randomly
selected FISH positive case would have a higher score than
a randomly chosen FISH negative case. In addition,
because the computer can distinguish varying levels of
intensity and area within this 2+ category, we chose a spe-
cific point on the ROC curve derived solely from 2+ cases
that yielded 100% sensitivity of FISH positive cases, while
minimizing the amount of false positive cases (Fig. 8).
This produced a cutoff point at a clinically desirable sen-
sitivity and specificity that was selected according to our
institutional staining variations. Leave-one-out cross vali-
dation experiments based on this cutoff showed promis-
ing improvement for equivocal cases when compared to
manual scoring. As all 2+ cases are considered positive by
Ventana scoring methods, usage of the Ma feature to ana-
lyze HER2 immunohistochemistry shows the possibility
of false positive rate reduction, which would lead to the
reduction of patients exposed to unnecessary treatment
toxicity. One advantage of our approach to measuring
HER2 staining is that unlike clinical scoring, which has
the ability of differentiating only 4 scoring levels, compu-
ter-assisted quantification outputs a nearly continuous
variable, for which fine tuned cut-offs can be identified.
Previously published systems differ in many respects from
our proposed algorithms. Firstly, many commercially
available systems have a universal cutoff score for HER2
overexpression that is not optimized for a given labora-
tory, in spite of well established variations in intra-labora-
tory conditions [14]. However, statistical analyses based
on the data collected from that particular institution can
provide a meaningful and institutional-specific, cutoff
value for immunostains such as HER2 [17]. ROC analysis
illustrates the benefits of adjusting for such variations
leading to improved sensitivity and specificity. With this
information, the selection of a particular cutoff score can
Simultaneous view of three scoring methods: Mn, FISH, and Manual Figure 6
Simultaneous view of three scoring methods: Mn, FISH, and Manual. Plot of mean intensity of stained membrane 
regions normalized by control (Mn) versus genetic amplification (FISH). Different colors denote manual scores. Arrows depict 
example cases whose classification was enhanced due to image-based analysis.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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be chosen according to each institution's operating
parameters, enabling pathologists to estimate the likeli-
hood that a certain score is correct based on the sensitivity
and specificity of the chosen cutoff point. In addition,
both commercial and noncommercial systems [16] have
thus far neglected to include the quantitative analysis of
positive HER2 controls in their calculation of a HER2
score. As evidenced in our study, there is sometimes
marked variation in staining intensity which is often
accounted for in manual scoring techniques, but
neglected in published computer-assisted methods. Con-
sequently, our algorithms specifically take into account
this variation in staining. And lastly, our algorithms are
morphologically based (unlike [16]), demonstrate
improvement in scoring 2+ cases, and freely available
(unlike many proprietary commercial systems) to further
research and improvement.
In the future, research efforts may be concentrated in
defining image features that better reflect percent of can-
cer cells stained (Table 1, Step E) or completeness of
membrane staining (Table 1, step D), and providing seg-
mentation algorithms that delineate the invasive compo-
nent of the carcinoma (Table 1, step B). Indeed, the
development of the image-based algorithms required to
fully assess HER2 immunohistochemistry is only in its
nascent stages, and what we have demonstrated here is
only a first step towards that goal. It is hoped that with the
combination of features that accurately quantify HER2
expression and the ability to distinguish not just 4 classes
of HER2 immunostaining, but rather a continuum, the
correlation between HER2 overexpression and response
to trastuzumab therapy can be enhanced.
Conclusion
This work has demonstrated the promise of developing
clinically based algorithms to assist in the quantification
of the HER2 immunostain. A membrane isolation algo-
rithm was developed that can be readily applied to quan-
tification of membrane stained images. In addition,
quantitative use of positive staining controls was shown
to significantly increase the diagnostic ability of the fea-
ROC Curves comparing Mn, Manual Scoring methods with Computer Assisted Image Analysis Figure 7
ROC Curves comparing Mn, Manual Scoring methods with Computer Assisted Image Analysis. These ROC 
curves report the sensitivity and specificity across all potential cutoff points for positive genetic amplification (≥ 2.3). In this 
plot, the quantitative use of controls (Mn)is shown to significantly increase the area under the ROC curve when compared to 
tissue analysis alone (Mp). The arrow denotes a point on the Ma curve where the false positive rate is significantly reduced 
compared to the 2+ point on the Manual Scoring curve. The AUC's of computer-assisted methods Mn and Mp are statistically 
similar to that of manual grading; only Ma is statistically different.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
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tures used to quantify HER2 membrane staining. The Mn
feature used showed similar ability to predict FISH posi-
tivity when compared to manual scoring. Furthermore,
potential improvement in specificity for the 2+ specimens
was demonstrated using the Ma feature. Lastly, by using
ROC analysis, we indicated a process by which an institu-
tion can derive a cutoff score for computer-assisted image
analysis systems that can account for their unique labora-
tory staining conditions. In the future, we hope to validate
this method by analyzing a larger series of independent
samples for which both IHC and FISH scores of HER2 are
available.
Indeed, we have shown that computer-assisted image-
analysis can enhance the degrees to which quantification
of immunohistochemistry can be achieved, and improve
the correlation of IHC with genetic amplification. Ulti-
mately, much investigation remains to be done in accu-
rately determining which patients not only overexpress
HER2, but also, which, in the end, will respond to ther-
apy.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BHH designed the study, wrote the membrane isolation
algorithm, carried out the image analysis, performed the
statistical analysis, and drafted the paper. MI–I contrib-
uted intellectually by suggesting the quantitative usage of
controls, and assisted in gathering images and patient
data. PJ contributed intellectually by focusing the study
on 2+ cases, reviewed all images, and assisted in gathering
patient data. WC provided the color decomposition algo-
rithm and critically reviewed the manuscript and experi-
ments. SG conceived of the study and intellectually
contributed to the discussion section. DJF provided fund-
ing, critical review of paper, and participated in the coor-
dination of the study. All authors read and reviewed the
final draft of the manuscript.
ROC curves based solely on equivocal 2+ cases for three scoring methods: Ma, Mn, and Manual Scoring Figure 8
ROC curves based solely on equivocal 2+ cases for three scoring methods: Ma, Mn, and Manual Scoring. The two 
left most arrows indicate significant decreases in false positive rate when using computer-assisted image analysis techniques. 
This may potentially show promise in reducing those patients who would otherwise be needlessly exposed to treatment toxic-
ity. The reduction may be attributed to not only the features used, but also the greater ability of computer-assisted analysis to 
differentiate more than just one cutoff point in the 2+ equivocal range.BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
Page 12 of 13
(page number not for citation purposes)
Additional material
Acknowledgements
This research was funded, in part, by a grant from the NIH through contract 
5R01EB003587-02 from the National Institute of Biomedical Imaging and 
Bioengineering. Additional Funds were provided by The Cancer Institute of 
New Jersey and the Department of Defense via contract # W81XWH-06-
1-0514.
References
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL:
Human breast cancer: correlation of relapse and survival
with amplification of the HER-2/neu oncogene.  Science 1987,
235(4785):177-182.
2. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The
product of the human c-erbB-2 gene: a 185-kilodalton glyco-
protein with tyrosine kinase activity.  Science 1986,
232(4758):1644-1646.
3. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer:
prognostic factor, predictive factor, and target for therapy.
Stem Cells 1998, 16(6):413-428.
4. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M,
Danyluk J, Godolphin W, Sliwkowski M, Akita R, et al.: Her-2/neu
expression in node-negative breast cancer: direct tissue
quantitation by computerized image analysis and association
of overexpression with increased risk of recurrent disease.
Cancer Res 1993, 53(20):4960-4970.
5. Leong TY, Leong AS: Controversies in the assessment of HER-
2: more questions than answers.  Adv Anat Pathol 2006,
13(5):263-269.
6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote
RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM,
Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube
SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF:
American Society of Clinical Oncology/College of American
Pathologists Guideline Recommendations for Human Epi-
dermal Growth Factor Receptor 2 Testing in Breast Cancer.
Arch Pathol Lab Med 2007, 131(1):18.
7. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon
DJ: Assessment of methods for tissue-based detection of the
HER-2/neu alteration in human breast cancer: a direct com-
parison of fluorescence in situ hybridization and immunohis-
tochemistry.  J Clin Oncol 2000, 18(21):3651-3664.
8. Bankfalvi A, Boecker W, Reiner A: Comparison of automated
and manual determination of HER2 status in breast cancer
for diagnostic use: a comparative methodological study
using the Ventana BenchMark automated staining system
and manual tests.  Int J Oncol 2004, 25(4):929-935.
9. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evalua-
tion of HER-2/neu gene amplification and overexpression:
comparison of frequently used assay methods in a molecu-
larly characterized cohort of breast cancer specimens.  J Clin
Oncol 2002, 20(14):3095-3105.
10. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote
RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM,
Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube
SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epider-
mal growth factor receptor 2 testing in breast cancer.  J Clin
Oncol 2007, 25(1):118-145.
11. Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan
S, Wians FH Jr., Hynan L, Ashfaq R: Assessment of HER-2/neu sta-
tus in breast cancer. Automated Cellular Imaging System
(ACIS)-assisted quantitation of immunohistochemical assay
achieves high accuracy in comparison with fluorescence in
situ hybridization assay as the standard.  Am J Clin Pathol 2001,
116(4):495-503.
12. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F,
Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ: Compar-
ison of immunohistochemistry by automated cellular imag-
ing system (ACIS) versus fluorescence in-situ hybridization
in the evaluation of HER-2/neu expression in primary breast
carcinoma.  Histopathology 2006, 48(3):258-267.
13. Bloom K, Harrington D: Enhanced accuracy and reliability of
HER-2/neu immunohistochemical scoring using digital
microscopy.  Am J Clin Pathol 2004, 121(5):620-630.
14. Leong AS: Quantitation in immunohistology: fact or fiction? A
discussion of variables that influence results.  Appl Immunohisto-
chem Mol Morphol 2004, 12(1):1-7.
15. Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS,
Gholap GA, Gholap AS, Barsky SH: Semi-automated imaging sys-
tem to quantitate Her-2/neu membrane receptor immuno-
reactivity in human breast cancer.  Cytometry A 2007,
71(5):273-285.
16. Skaland I, Ovestad I, Janssen EAM, Klos J, Kjellevold KH, Helliesen T,
Baak JP: Comparing subjective and digital image analysis
HER2/neu expression scores with conventional and modified
FISH scores in breast cancer.  Journal of Clinical Pathology 2008,
61:68-71.
17. Seidal T, Balaton AJ, Battifora H: Interpretation and quantifica-
tion of immunostains.  Am J Surg Pathol 2001, 25(9):1204-1207.
18. Chen W RM Foran DJ.: A prototype for unsupervised analysis
of tissue microarrays for cancer research and diagnostics.
IEEE Transactions on Information Technology in Biomedicine 2004,
8(2):89-96.
19. Ventana Scoring Guide   [http://www.ventanamed.com/products/
files/ScoringGuide.pdf]
20. Otsu N: A threshold selection method from gray-level histo-
grams.  IEEE Trans Sys, Man, Cyber 1979, 9(1):62-66.
Additional file 1
Selecting the optimal threshold for membrane pixels. Although lower 
thresholds can produce visually more satisfying membrane isolation results 
for weaker staining cases (especially IHC = 1+), responses greater than 15 
produced the greatest area under the ROC curve using the Mn feature, and 
thus the k = 15 threshold was selected to produce the results in these exper-
iments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2342-8-11-S1.tiff]
Additional file 2
Membrane Isolation Algorithm results using both high and low 
thresholds. These are the results from the membrane isolation algorithm 
using 2 different thresholds k = 15, and k = 5. These are specimens which 
stained less intensely.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2342-8-11-S2.pdf]
Additional file 3
ROC curves using Membrane Isolation Algorithm based on k = 15 and 
a combination (k = 15, k = 5). This is a comparison of ROC curves based 
on different Membrane Isolation Algorithm (MIA) variations. Since 
lighter cases showed enhanced membrane isolation detection when lower 
thresholds were used, a MIA using k = 5 threshold for lighter images and 
k = 15 for darker images was evaluated (green line). However, this did 
not improve AUC in comparison to one universal threshold (black line), 
and consequently, only one threshold (k = 15) was used in the results of 
this manuscript. It is interesting to note that the combination threshold 
used had very similar results to manual scoring (blue line).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2342-8-11-S3.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Imaging 2008, 8:11 http://www.biomedcentral.com/1471-2342/8/11
Page 13 of 13
(page number not for citation purposes)
21. Varma M, Zisserman A: A statistical approach to texture classi-
fication from single images.  INT J COMPUT VISION 2005, 62(1-
2):61-81.
22. DeLong ER DDM Clarke-Pearson DL: Comparing the Area
Under Two or More Correlated Receiver Operating Charac-
teristic Curves:  A Nonparametric Approach.  Biometrics 1988,
44:837-845.
23. VassarStats: Web Site for Statistical Computation   [http://
faculty.vassar.edu/lowry/VassarStats.html]
24. McNemar Q: Note on the sampling error of the difference
between correlated proportions or percentages.  Psy-
chometrika 1947, 12:153-157.
25. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Pana-
geas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M,
Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristo-
fanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly
trastuzumab and paclitaxel therapy for metastatic breast
cancer with analysis of efficacy by HER2 immunophenotype
and gene amplification.  J Clin Oncol 2001, 19(10):2587-2595.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2342/8/11/prepub